Health
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies
- Sales of cheaper compounded versions must stop within 90 days
- Novo’s rival shots, Ozempic and Wegovy, remain in short supply
This article is for subscribers only.
Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat versions in the coming months.
The US Food and Drug Administration determined that the drug shortage “is resolved,” reaffirming its earlier decision that compounders challenged in court. Such companies, which are allowed to make copies of medicines when they are in short supply, must stop copying Lilly’s drugs in the next 60 to 90 days, the agency said.